International Journal of Clinical Oncology

, Volume 10, Issue 6, pp 405–410 | Cite as

Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer

  • Hiroji Uemura
  • Hisashi Hasumi
  • Takashi Kawahara
  • Shinpei Sugiura
  • Yasuhide Miyoshi
  • Noboru Nakaigawa
  • Jun-ichi Teranishi
  • Kazumi Noguchi
  • Hitoshi Ishiguro
  • Yoshinobu Kubota
ORIGINAL ARTICLE

Abstract

Background

We previously demonstrated that an angiotensin II receptor blocker (ARB) had the potential to inhibit cell proliferation of prostate cancer. In this study, we examined whether an ARB could elicit an antiproliferative effect on hormone-refractory prostate cancer, clinically.

Methods

Twenty-three patients with advanced hormone-refractory prostate cancer who had already received secondary hormonal therapy using dexamethasone, and who were no longer receiving conventional therapy, were enrolled. All of the patients received candesartan 8 mg once daily per os and, simultaneously, androgen ablation. Change in prostate-specific antigen (PSA) was determined as the primary endpoint. The secondary end-point was change in performance status (PS). To investigate angiotensin II type 1 (AT1) receptor expression in prostate cancer tissue, real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was performed, using specimens, from untreated patients with prostate cancer.

Results

Eight patients (34.8%) showed responsive PSA changes; six showed a decrease immediately after starting administration and two showed a stable level of PSA. Six men with a PSA decline of more than 50% showed an improvement in PS. The mean time to PSA progression (TTPP) in responders was 8.3 months (range, 1–24 months). Half of the patients showed stable or improved PS during treatment. With regard to toxic effects, only one patient showed hypotension during treatment. The RT-PCR showed that AT1 receptor expression in well-differentiated adenocarcinoma was higher than that in poorly differentiated adenocarcinoma.

Conclusion

These data showed that an ARB had potential biological effects on prostate cancer, suggesting the usefulness of the cytostatic activity of such agents on recurrent prostate cancer.

Key words

Angiotensin II receptor blocker Hormone-refractory prostate cancer Prostate-specific antigen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal, A, Thomas, A, Murray, T,  et al. 2002Cancer StatisticsCA Cancer J Clin522347PubMedCrossRefGoogle Scholar
  2. 2.
    The Research Group for Population-Based Cancer Registration in Japan2004

    Cancer incidence in Japan

    Tajima, KKuroishi, TOshima, A eds. Cancer mortality and morbidity statistics. Monograph on cancer research, No. 51Japan Scientific Societies PressKarger, Tokyo9599
    Google Scholar
  3. 3.
    Petrylak, DP, Tangen, CM, Hussain, MH,  et al. 2004Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med35115131520PubMedCrossRefGoogle Scholar
  4. 4.
    Liu, G, Oettel, K, Ripple, G,  et al. 2002Phase I trial of 1 alpha-hydroxyvitamin D (2) in patients with hormone refractory prostate cancerClin Cancer Res828202827PubMedGoogle Scholar
  5. 5.
    Liu, G, Wilding, G, Staab, MJ,  et al. 2003Phase II study of 1 alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancerClin Cancer Res940774083PubMedGoogle Scholar
  6. 6.
    Carducci, MA, Padley, RJ, Breul, JV,  et al. 2003Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trialJ Clin Oncol21679689PubMedCrossRefGoogle Scholar
  7. 7.
    Nelson, JB, Nabulsi, AA, Vogelzang, NJ,  et al. 2003Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentanJ Urol16911431149PubMedGoogle Scholar
  8. 8.
    Fujiyama, S, Matsubara, H, Nozawa, Y,  et al. 2001Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivationCirc Res882229PubMedGoogle Scholar
  9. 9.
    Uemura, H, Ishiguro, H, Nakaigawa, N,  et al. 2003Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factorMol Cancer Ther211391147PubMedGoogle Scholar
  10. 10.
    Bubley, GJ, Carducci, M, Dahut, W,  et al. 1999Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working GroupJ Clin Oncol1734613467PubMedGoogle Scholar
  11. 11.
    Ishiguro, H, Nakaigawa, N, Miyoshi, Y,  et al. 2005Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin, are overexpressed and associated with prostate cancer progressionProstate6492100PubMedCrossRefGoogle Scholar
  12. 12.
    Hasumi, H, Ishiguro, H, Nakamura, M,  et al. 2005Neuroserpin (pi-12) is up-regulated in high-grade prostate cancer and is associated with survivalInt J Cancer115911916PubMedCrossRefGoogle Scholar
  13. 13.
    Hahn, AW, Jonas, U, Buhler, FR,  et al. 1994Activation of human peripheral monocytes by angiotensin IIFEBS Lett347178180PubMedCrossRefGoogle Scholar
  14. 14.
    Rice, EK, Tesch, GH, Cao, Z,  et al. 2003Induction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin IIKidney Int6312651275PubMedCrossRefGoogle Scholar
  15. 15.
    Sato, H, Watanabe, A, Tanaka, T,  et al. 2003Regulation of the human tumor necrosis factor-alpha promoter by angiotensin II and lipopolysaccharide in cardiac fibroblasts: different cis-acting promoter sequences and transcriptional factorsJ Mol Cell Cardiol3511971205PubMedCrossRefGoogle Scholar
  16. 16.
    Amann, B, Tinzmann, R, Angelkort, B 2003ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1Diabetes Care2624212425PubMedGoogle Scholar
  17. 17.
    Moskowitz, DW, Johnson, FE 2004The central role of angiotensin-converting enzyme in vertebrate pathophysiologyCurr Top Med Chem414331454PubMedCrossRefGoogle Scholar
  18. 18.
    Lever, AF, Hole, DJ, Gillis, CR,  et al. 1998Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?Lancet352179184PubMedCrossRefGoogle Scholar
  19. 19.
    Ullian, ME, Walsh, LG, Morinelli, TA 1996Potentiation of angiotensin II action by corticosteroids in vascular tissueCardiovasc Res32266273PubMedCrossRefGoogle Scholar
  20. 20.
    Guo, DF, Uno, S, Inagami, T 1995Steroid hormones upregulate rat angiotensin II type 1A receptor gene: role of glucocorticoid responsive elements in rat angiotensin II type 1A promoterJ Steroid Biochem Mol Biol536973PubMedCrossRefGoogle Scholar
  21. 21.
    Sano, M, Fukuda, K, Sato, T,  et al. 2001ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblastsCirc Res89661669PubMedGoogle Scholar
  22. 22.
    Logothetis, CJ, Wu, KK, Finn, LD,  et al. 2001Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancerClin Cancer Res711981203PubMedGoogle Scholar
  23. 23.
    Egami, K, Murohara, T, Shimada, T,  et al. 2003Role of host angiotensin II type 1 receptor in tumor angiogenesis and growthJ Clin Invest1126775PubMedCrossRefGoogle Scholar
  24. 24.
    Ingber, D, Fujita, T, Kishimoto, S,  et al. 1990Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growthNature348555557PubMedCrossRefGoogle Scholar
  25. 25.
    Yamaoka, M, Yamamoto, T, Masaki, T,  et al. 1993Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470)Cancer Res5342624267PubMedGoogle Scholar
  26. 26.
    Hall, MC, Troncoso, P, Pollack, A,  et al. 1994Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapyUrology44869875PubMedGoogle Scholar
  27. 27.
    Figg, WD, Dahut, W, Duray, P,  et al. 2001A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancerClin Cancer Res718881893PubMedGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2005

Authors and Affiliations

  • Hiroji Uemura
    • 1
  • Hisashi Hasumi
    • 1
  • Takashi Kawahara
    • 1
  • Shinpei Sugiura
    • 1
  • Yasuhide Miyoshi
    • 1
  • Noboru Nakaigawa
    • 1
  • Jun-ichi Teranishi
    • 2
  • Kazumi Noguchi
    • 2
  • Hitoshi Ishiguro
    • 1
  • Yoshinobu Kubota
    • 1
  1. 1.Department of UrologyYokohama City University Graduate School of MedicineYokoyamaJapan
  2. 2.Department of UrologyYokohama City University Medical CenterYokohamaJapan

Personalised recommendations